Worth the risk? Relationship of incentives to risk and benefit perceptions and willingness to participate in schizophrenia research

Schizophrenia Bulletin

Volumn 35, Issue 4, 2009, Pages 730-737

  Dunn, Laura B ^a   Kim, Daniel S ^b,c   Fellows, Ian E ^b   Palmer, Barton W ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Ethics; Incentives; Informed consent; Research participation; Risk perception; Voluntarism

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL RESEARCH; COGNITION; COMPENSATION; COMPREHENSION; CORRELATIONAL STUDY; FEMALE; FINANCIAL MANAGEMENT; HUMAN; INFORMED CONSENT; MALE; MEDICAL ETHICS; PERCEPTION; PRIORITY JOURNAL; RATING SCALE; RISK; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TASK PERFORMANCE; VIGNETTE; CLINICAL TRIAL; COMPARATIVE STUDY; DECISION MAKING; ETHICS; MENTAL CAPACITY; METHODOLOGY; MIDDLE AGED; MOTIVATION; PATIENT PARTICIPATION; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RESEARCH ETHICS; RESEARCH SUBJECT;

CLINICAL TRIALS AS TOPIC; DECISION MAKING; ETHICS, RESEARCH; FEMALE; HUMANS; INFORMED CONSENT; MALE; MENTAL COMPETENCY; MIDDLE AGED; MOTIVATION; PATIENT PARTICIPATION; PSYCHIATRIC STATUS RATING SCALES; RESEARCH DESIGN; RESEARCH SUBJECTS; RISK ASSESSMENT; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 68149158300     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbn003     Document Type: Article

References (46)

1. DeRenzo EG. Coercion in the recruitment and retention of human research subjects, pharmaceutical industry payments to physician-investigators, and the moral courage of the IRB. IRB. 2000;35(4):730-737
2. Department of Health and Human Services Office of Inspector General. Recruiting Human Subjects: Pressures in Industry-Sponsored Clinical Research. OEI-01-97-00195. 2000. http:// oig.hhs.gov/oei/reports/oei-01-97-00195.pdf.
3. Pace C, Miller FG, Danis M. Enrolling the uninsured in clinical trials: an ethical perspective. Crit Care Med. 2003;31 (suppl 3):S121-S125.
4. Rosenstein DL, Miller FG. Ethical considerations in psycho- pharmacological research involving decisionally impaired subjects. Psychopharmacology (Berl). 2003;171(1):92-97.
5. Gross CP, Mallory R, Heiat A, Krumholz HM. Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med. 2002;137(1):10-16.
6. Grady C, Dickert N, Jawetz T, Gensler G, Emanuel E. An analysis of U.S. practices of paying research participants. Contemp Clin Trials. 2005;26(3):365-375.
7. Macklin R. 'Due' and 'undue' inducements: on paying money to research subjects. IRB. 1981;3(5):1-6.
8. Emanuel EJ. Ending concerns about undue inducement. J Law Med Ethics. 2004;32(1):100-105.
9. Nelson RM, Merz JF. Voluntariness of consent for research: an empirical and conceptual review. Med Care. 2002;40(suppl 9):V69-V80.
10. Grant RW, Sugarman J. Ethics in human subjects research: do incentives matter? J Med Philos. 2004;29(6):717-738.
11. Wilkinson M, Moore A. Inducement in research. Bioethics. 1997;11(5):373-389.
12. Dunn LB, Gordon NE. Improving informed consent and enhancing recruitment for research by understanding economic behavior. JAMA. 2005;293:609-612.
13. Bentley JP, Thacker PG. The influence of risk and monetary payment on the research participation decision making process. J Med Ethics. 2004;30(3):293-298.
14. Halpern SD, Karlawish JH, Casarett D, Berlin JA, Asch DA. Empirical assessment of whether moderate payments are undue or unjust inducements for participation in clinical trials. Arch Intern Med. 2004;164(7):801-803.
15. Shore D. Ethical issues in schizophrenia research: a commentary on some current concerns. Schizophr Bull. 2006;32(1): 26-29.
16. Appelbaum PS. Decisional capacity of patients with schizophrenia to consent to research: taking stock. Schizophr Bull. 2006;32(1):22-25.
17. Marson DC, Phillips J. Financial capacity in persons with schizophrenia and severe mental illness: clinical and ethical aspects. Schizophr Bull. 2006;32(1):81-91.
18. Roberts LW, Warner TD, Hammond KG, Dunn LB. Assessments by patients with schizophrenia and psychiatrists of relative risk of research procedures. Psychiatr Serv. 2006; 57(11):1629-1635.
19. Dunn LB, Candilis PJ, Roberts LW. Emerging empirical evidence on the ethics of schizophrenia research. Schizophr Bull. 2006;32(1):47-68.
20. Roberts LW. Informed consent and the capacity for voluntarism. Am J Psychiatry. 2002;159(5):705-712.
21. Roberts LW, Dunn LB, Green Hammond KA, Warner TD. Do research procedures pose relatively greater risk for healthy persons than for persons with schizophrenia? Schiz-ophr Bull. 2006;32(1):153-158.
22. Grisso T, Appelbaum PS. The MacArthur Treatment Competence Study. III: abilities of patients to consent to psychiatric and medical treatments. Law Hum Behav. 1995;19(2): 149-174.
23. Roberts LW, Roberts B. Psychiatric research ethics: an overview of evolving guidelines and current ethical dilemmas in the study of mental illness. Biol Psychiatry. 1999;46(8): 1025-1038.
24. Palmer BW, Savla GN. The association of specific neu-ropsychological deficits with capacity to consent to research or treatment. J Int Neuropsychol Soc. 2007;13(6):1047-1059.
25. Roberts LW, Warner TD, Brody JL, Roberts B, Lauriello J, Lyketsos C. Patient and psychiatrist ratings of hypothetical schizophrenia research protocols: assessment of harm potential and factors influencing participation decisions. Am J Psychiatry. 2002;159(4):573-584.
26. Roberts LW, Warner TD, Nguyen KP, Geppert CM, Rogers MK, Roberts BB. Schizophrenia patients' and psychiatrists' perspectives on ethical aspects of symptom re-emergence during psychopharmacological research participation. Psy-chopharmacology (Berl). 2003;171(1):58-67.
27. Roberts LW, Hammond KG, Hoop J. An inverse relationship between perceived harm and participation willingness in schizophrenia research protocols. Am J Psychiatry. 2006; 163(11):2002-2004.
28. Tversky A, Kahneman D. The framing of decisions and the psychology of choice. Science. 1981;211(4481):453-458.
29. Dunn LB, Palmer BW, Appelbaum PS, Saks ER, Aarons GA, Jeste DV. Prevalence and correlates of adequate performance on a measure of abilities related to decisional capacity: differences among three standards for the MacCAT-CR in patients with schizophrenia. Schizophr Res. 2007;89(1-3):110-118.
30. Evans JD, Heaton RK, Paulsen JS, McAdams LA, Heaton SC, Jeste DV. Schizoaffective disorder: a form of schizophrenia or affective disorder? J Clin Psychiatry. 1999;60(12): 874-882.
31. Mattis S. Dementia Rating Scale. Odessa, FL: Psychological Assessment Resources, Inc.; 1973.
32. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12(3):426-445.
33. Palmer BW, Heaton RK, Paulsen JS, et al. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsy-chology. 1997;11(3):437-446.
34. Roberts LW, Warner TD, Brody JL. Perspectives of patients with schizophrenia and psychiatrists regarding ethically important aspects of research participation. Am J Psychiatry. 2000;157(1):67-74.
35. Candilis PJ, Geppert CM, Fletcher KE, Lidz CW, Appelbaum PS. Willingness of subjects with thought disorder to participate in research. Schizophr Bull. 2006;32(1): 159-165.
36. Lidz CW, Appelbaum PS. The therapeutic misconception: problems and solutions. Med Care. 2002;40(suppl 9):V55-V63.
37. Redelmeier DA, Rozin P, Kahneman D. Understanding patients' decisions. Cognitive and emotional perspectives. JAMA. 1993;270(1):72-76.
38. Kemp R, Chua S, McKenna P, David A. Reasoning and delusions. Br J Psychiatry. 1997;170:398-405.
39. Huq SF, Garety PA, Hemsley DR. Probabilistic judgements in deluded and non-deluded subjects. Q J Exp Psychol A. 1988; 40(4):801-812.
40. Verheggen FW, Nieman F, Jonkers R. Determinants of patient participation in clinical studies requiring informed consent: why patients enter a clinical trial. Patient Educ Couns. 1998;35(2):111-125.
41. Roberts LW, Warner TD, Anderson CT, Smithpeter MV, Rogers MK. Schizophrenia research participants' responses to protocol safeguards: recruitment, consent, and debriefing. Schizophr Res. 2004;67(2-3):283-291.
42. Twamley EW, Doshi RR, Nayak GV, et al. Generalized cognitive impairments, ability to perform everyday tasks, and level of independence in community living situations of older patients with psychosis. Am J Psychiatry. 2002;159(12): 2013-2020.
43. Savla GN, Moore DJ, Palmer BW. Cognitive functioning in schizophrenia. In: Mueser KT, Jeste DV, eds. Clinical Handbook of Schizophrenia. New York, NY: Guilford Press; In press.
44. Dunn LB, Palmer BW, Keehan M, Jeste DV, Appelbaum PS. Assessment of therapeutic misconception in older schizophrenia patients with a brief instrument. Am J Psychiatry. 2006; 163(3):500-506.
45. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. http://www.hhs.gov/ohrp/ humansubjects/ guidance/belmont.htm. Accessed October 5, 2006.
46. Palmer BW, Dunn LB, Appelbaum PS, et al. Assessment of capacity to consent to research among older persons with schizophrenia, Alzheimer disease, or diabetes mellitus: comparison of a 3-item questionnaire with a comprehensive standardized capacity instrument. Arch Gen Psychiatry. 2005;62(7): 726-733.